PhaseBio Pharmaceuticals, Inc. (PHAS)

$0.0701

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol PHAS
Price $0.0701
Beta 2.869
Volume Avg. 1.79M
Market Cap 3.495M
Shares () -
52 Week Range 0.041-4.08
1y Target Est -
DCF Unlevered PHAS DCF ->
DCF Levered PHAS LDCF ->
ROE -30.95% Strong Sell
ROA 126.77% Strong Buy
Operating Margin -
Debt / Equity -118.88% Sell
P/E -0.03 Neutral
P/B -0.03 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PHAS news


Mr. Jonathan Mow
Healthcare
Biotechnology
NASDAQ Global Market

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.